Protein KIAA1522: A Potential Drug Target and Biomarker (G57648)

Target Name: KIAA1522

NCBI ID: G57648

KIAA1522

Protein KIAA1522: A Potential Drug Target and Biomarker

Protein KIAA1522, also known as isoform 2, is a highly conserved non-coding RNA molecule that plays a crucial role in the development and maintenance of tissues, including neural cells, tissues, and organs. Its function is highly conserved across various species, and it has been implicated in various physiological processes, including cell growth, differentiation, and survival.

KIAA1522 has been the focus of intense research in recent years due to its potential involvement in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its role in these diseases has led to the identification of its potential as a drug target or biomarker. In this article, we will explore the uncharacterized protein KIAA1522, its potential drug targets, and its potential as a biomarker for various diseases.

The Uncharacterized Protein KIAA1522

KIAA1522 is a short non-coding RNA molecule that consists of 199 amino acid residues. It is highly conserved across various species, and its sequence is highly conserved among different organisms, including humans. KIAA1522 is expressed in various tissues and organs, including brain, heart, liver, kidney, and pancreas.

KIAA1522 has been shown to play a role in various physiological processes, including cell growth, differentiation, and survival. For example, studies have shown that KIAA1522 can promote the growth and survival of cancer cells (8) and can also play a role in the development and progression of neurodegenerative diseases.

Potential Drug Targets

KIAA1522 has been identified as a potential drug target due to its involvement in various diseases. Its potential drug targets include cell signaling pathways, cell adhesion, and cellular processes that are involved in cancer progression.

One of the potential drug targets for KIAA1522 is the PI3K/Akt signaling pathway. This signaling pathway is involved in various cellular processes, including cell growth, survival, and angiogenesis. KIAA1522 has been shown to play a role in the regulation of this pathway, and alterations in its expression have been implicated in various diseases, including cancer.

Another potential drug target for KIAA1522 is the TGF-灏? signaling pathway. This signaling pathway is involved in cell growth, differentiation, and survival. KIAA1522 has been shown to play a role in the regulation of this pathway, and alterations in its expression have been implicated in various diseases, including neurodegenerative diseases.

Potential Biomarkers

KIAA1522 has also been identified as a potential biomarker for various diseases. Its expression has been shown to be affected by various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

For example, studies have shown that KIAA1522 is downregulated in various cancer tissues, and its expression is associated with poor prognosis. Similarly, studies have shown that KIAA1522 is expressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition, KIAA1522 has also been shown to be involved in various developmental disorders, including Down syndrome and Fragile X syndrome.

Conclusion

In conclusion, the uncharacterized protein KIAA1522 has shown to play a role in various physiological processes and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand its role in these processes and its potential as a drug or biomarker.

Protein Name: KIAA1522

The "KIAA1522 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIAA1522 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets